Experimental treatment approach shows potential against Staphylococcus aureus

January 16, 2019

A new class of engineered proteins may counter infection caused by Staphylococcus aureus - a bacterial species considered one of the largest global health threats, a new study suggests.

Published online January 16 in Science Translational Medicine, the study is the result of a five-year research partnership between scientists at NYU School of Medicine and Janssen Research & Development, LLC (Janssen).

"To our knowledge, this is the first report showing that proteins called centyrins can potently block the effects of severe S. aureus bacterial infections in mice, and in human cell experiments," says lead study author Victor Torres, PhD, associate professor in the Department of Microbiology at NYU Langone Health.

The preclinical study found that a select group of centyrins interfered with the action of five toxins that S. aureus depends on for escaping the human immune system and invading tissues. By taking away the bacteria's ability to thrive without destroying it, the new approach could help to address antibiotic resistance, the problem where treatments destroy some bacterial strains, only to make more space for others less vulnerable to available antibiotics over time.

Nearly one-third of the human population are carriers of S. aureus, generally without symptoms. But for those with weakened immune systems, S. aureus infection may result in life-threatening lung, heart, bone, or bloodstream infections, says Torres. S. aureus has long posed a threat in hospitals. Strains that have become resistant to many antibiotics (including methicillin) are called methicillin-resistant S. aureus (MRSA), which leads to 11,000 deaths in the United States each year.

"MRSA remains a major threat because generations of treatment and vaccine attempts have failed to control it," says Torres. "Our study responds to an urgent need for new thinking in anti-staphylococcal therapeutics."

Road to a New Treatment Class

Researchers (including current NYU Langone faculty member Shohei Koide, PhD) discovered a class of proteins derived from fibronectin type III (FN3) protein subunits (domains) in 1998, which were originally called monobodies and explored for their anti-cancer potential. Centyrins, FN3 "scaffolds" optimized for pharmaceutical development, were subsequently used by Janssen for the discovery of anti-toxin versions.

Torres and others in the field spent years learning that S. aureus thrives by releasing toxins, one of which, leukocidin AB, was identified by his lab. Such toxins bore holes in immune cells, destroying them before they can destroy the bacteria. They also bore into red blood cells, which flood bacteria with nutrients when they die and burst.

Building on this work, the current study authors used a molecular biology technique to make changes in a single parental centyrin, creating a trillion slightly different centyrins - and nearly all at once thanks to automation. Out of this vast "library," careful screening revealed 209 centyrins that happened to bind to pieces of one of the five major S. aureus leukotoxins. Those that bound the tightest were shown by the current research team, in experiments using human cells, to prevent the toxins from attaching to and destroying the cells they would otherwise bore into.

The research team then gave mice a toxic dose of LukED S. aureus toxin. Those also given ahead of time a dose of the parental scaffold centyrin (not designed to bind to this toxin) died. However, those given the centyrin called SM1S26 - chosen for its ability to interfere with the LukED S. aureus toxin - lived. Even in experiments in which mice received the anti-toxin centyrin four hours after they were infected with live S. aureus (a scenario more closely resembling clinical reality), 50 percent of the infected animals survived compared to none in the control group of infected mice.

Moving forward, the collaborative research team is also developing biologics that combine centyrins with anti-staphylococcal monoclonal antibodies (mABs) in a new class of proteins called MABtyrins, which could be more effective at neutralizing S. aureus.

"One of the most exciting aspects of this work is that scientists may be able to pick their pathogen, and then easily generate a vast, cost-effective library of centyrins shaped to interfere with the disease process at hand," says Torres. "It's bigger than one experimental treatment."
-end-
Along with Torres, the study was led by co-corresponding author, Anthony Simon Lynch, PhD, Senior Scientific Director at Janssen Research & Development, LLC. First authors of the paper were Rita Chan, Aidan O'Malley, and William Sause, PhD, of the Department of Microbiology at NYU School of Medicine, and Peter Buckley, PhD, of Janssen. Study authors were Francis Alonzo 3rd, PhD, and Kristina Boguslawski at NYU; and Angela Payne, Jeffrey Fernandez, William Strohl, PhD, and Brian Whitaker of Janssen.

This work was solely supported by Janssen Research & Development, LLC of Spring House, PA. NYU and Torres have a research and licensing agreement with Janssen, which is responsible for the development of potential therapeutics stemming from the joint research effort. The specific terms of this arrangement are being managed in accordance with the policies of NYU Langone. Work in the Torres lab is also funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH-NIAID). Torres is also a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Diseases.

NYU Langone Health / NYU School of Medicine

Related Staphylococcus Aureus Articles from Brightsurf:

Vaccine that harnesses antifungal immunity protects mice from staph infection
Immunization of mice with a new vaccine consisting of fungal particles loaded with Staphylococcus aureus (S. aureus) proteins protects mice against S. aureus infection, according to a study published August 20 2020 in the open-access journal PLOS Pathogens by David Underhill of Cedars-Sinai Medical Center, and colleague.

New strategy emerges for vaccine against methicillin-resistant staphylococcal aureus
Experiments in mice have shown early success in vaccinating them against potentially deadly bacterial infections, such as methicillin-resistant Staphylococcal aureus, or MRSA, the strain resistant to most drug treatments.

Ways to disrupt protein synthesis in Staphylococcus aureus found
It is well known that many strains of Staphylococcus are resistant to antibiotics, and research groups around the world seek new targets in the bacteria to decrease their infectious potential.

Protective shield: How pathogens withstand acidic environments in the body
Certain bacteria, including the dangerous nosocomial pathogen MRSA, can protect themselves from acidic conditions in our body and thus ensure their survival.

One of the mechanisms of Staphylococcus antibiotic resistance deciphered
The Russian side is represented by Structural Biology Lab (Kazan Federal University) and Institute of Proteins (Russian Academy of Sciences).

Trial shows using two drugs not better than one when treating MRSA blood infections
Researchers attempting to improve the treatment for methicillin-resistant Staphylococcus aureus (MRSA) blood infections have discovered the combination of two antibiotics was no better than one, and led to more adverse effects.

Solution of the high-resolution crystal structure of stress proteins from Staphylococcus
One of the main factors favoring a microorganism's survival in extreme conditions is preserving ribosomes -- a macromolecular complex comprising RNA and proteins

A common skin bacterium put children with severe eczema at higher risk of food allergy
In a new study published today in the Journal of Allergy and Clinical Immunology, scientists from King's College London have found that young children with severe eczema infected with Staphylococcus aureus (SA) bacterium, are at a higher risk of developing a food allergy.

National handwashing campaign reduces incidence of Staphylococcus aureus infection in Australia's hospitals
Since its implementation in 2009, the National Australian Hand Hygiene Initiative (NHHI) has seen significant, sustained improvements in hand hygiene compliance among Australian healthcare workers, and reduced risks of potentially fatal healthcare-associated Staphylococcus aureus infection, according to new research being presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam.

Experimental treatment approach shows potential against Staphylococcus aureus
A new class of engineered proteins may counter infection caused by Staph aureus.

Read More: Staphylococcus Aureus News and Staphylococcus Aureus Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.